Amarin Corporation (NASDAQ: AMRN) shares got a major boost during the pre-market hours of Thursday after it said the American Diabetes Association (ADA) has noted updates related to the results of its REDUCE-IT study in the annual Standards of Medical Care in Diabetes report.
AMRN shares jumped 9.5% during the morning trade. The stock has gained 38% since the beginning of this year.
The ADA is a non-profit organization that works to spread awareness about diabetes, besides raising funds for researches taking place in this field. As a general policy, the organization does not endorse or certify any specific brands.
ADA’s findings relate to icosapent ethyl, which Amarin markets under the brand name Vascepa capsules. Vascepa has received FDA approval to cut down triglyceride levels in adult patients. The Dublin, Ireland-based firm has, meanwhile, commenced transmission of data to the FDA seeking an expansion of the Vascepa FDA label based on the landmark REDUCE-IT results.
READ: AMARIN SHARES JUMP ON RUMORS OVER NOVARTIS INTEREST
The FDA is yet to review this application, but investors are hoping that ADA’s reference would now help fast-track the process.
In the Standard of Care recommendation, ADA notes, “…based on the outcome of Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT), which determined the addition of icosapent ethyl to statin therapy for patients with high triglyceride levels reduced cardiovascular events.”
READ: WHAT IS NASH AND WHICH BIOTECH FIRMS ARE VYING FOR THE FIRST-MOVER STATUS
Meanwhile, it also added, “It should be noted that data are lacking with other omega-3 fatty acids, and results of the REDUCE-IT trial should not be extrapolated to other products.”
Earlier last month, shares of Amarin Corp rallied 14% on rumors that Novartis (NVS) is looking to buy the Dublin-based firm. There have been no further updates on the same.
Listen to on-demand earnings calls and hear how management responds to analysts’ questions
Most Popular
Cost reduction has become a priority for FedEx (FDX) after a challenging quarter
Shares of FedEx Corporation (NYSE: FDX) were up 1% on Tuesday. The stock has dropped 44% year-to-date and 34% over the past 12 months. The company delivered mixed results for
Prime Medicine is the next big biotech to pursue IPO. Here’s all you need to know
After a soft start to the year, the IPO market has witnessed muted activity so far though a few big companies entered the stock market. On the heels of AIG
Stock Watch: Is Darden Restaurants a good buy after earnings?
After a prolonged slowdown, the restaurant industry is returning to normal patterns but macroeconomic uncertainties and high inflation are currently playing spoilsport for it. While the pandemic-related slump forced many
